Encala’s mechanism of action leads to improved absorption of the healthy calories in Encala as well as other fat and fat-soluble vitamins in the accompanying meal. The therapy was proven to be efficacious, safe, and well-tolerated in patients with cystic fibrosis and exocrine pancreatic insufficiency in a study sponsored by the National Institutes of Health.
“Envara Health is committed to putting our unique structured lipid platform to work to improve how patients manage their malabsorption issues,” said Jim O’Connell, Envara Health’s CEO and Co-Founder.
O’Connell explained that the product is a taste-neutral, plant-based powder that is a source of highly absorbable long-chain fats, including essential fatty acids. The therapy is recommended for use under medical supervision in adults and children over one year of age to help meet their weight and nutritional needs.
According to O’Connell, there is tremendous potential for this new technology to revolutionize clinical nutrition across a broad range of issues. He said that the company is developing a suite of infant products for the earliest stages of life, as well as liquid formulations, and a powder format for adolescents, adults and seniors.
“So we have a lot to keep us busy,” laughed O’Connell.
